Home LiteratureArticle Details
PMID: 21642542 Published · ppublish English Journal Article Research Support, N.I.H., Extramural

Knockdown of HMGB1 in tumor cells attenuates their ability to induce regulatory T cells and uncovers naturally acquired CD8 T cell-dependent antitumor immunity.

Journal of immunology (Baltimore, Md. : 1950) ·Vol. 187 ·No. 1 ·2011-07-01 ·Pages 118-25

Liu Z, Falo LD, You Z

Abstract

Although high mobility group box 1 (HMGB1) in tumor cells is involved in many aspects of tumor progression, its role in tumor immune suppression remains elusive. Host cell-derived IL-10 suppressed a naturally acquired CD8 T cell-dependent antitumor response. The suppressive activity of tumor-associated Foxp3(+)CD4(+)CD25(+) regulatory T cells (Treg) was IL-10 dependent. Neutralizing HMGB1 impaired tumor cell-promoted IL-10 production by Treg. Short hairpin RNA-mediated knockdown of HMGB1 (HMGB1 KD) in tumor cells did not affect tumor cell growth but uncovered naturally acquired long-lasting tumor-specific IFN-γ- or TNF-α-producing CD8 T cell responses and attenuated their ability to induce Treg, leading to naturally acquired CD8 T cell- or IFN-γ-dependent tumor rejection. The data suggest that tumor cell-derived HMGB1 may suppress naturally acquired CD8 T cell-dependent antitumor immunity via enhancing Treg to produce IL-10, which is necessary for Treg-mediated immune suppression.

MeSH Terms
Animals Antigens, Neoplasm/biosynthesis,genetics,physiology CD8-Positive T-Lymphocytes/immunology,metabolism,pathology Cell Differentiation/genetics,immunology Cell Line, Tumor Colonic Neoplasms/immunology,pathology,prevention & control Female Gene Knockdown Techniques HMGB1 Protein/deficiency,genetics,physiology Humans Immunity, Innate/genetics Interleukin-10/biosynthesis,genetics,physiology Mammary Neoplasms, Experimental/immunology,pathology,prevention & control Mice Mice, Inbred BALB C Mice, Inbred C57BL Mice, Knockout Mice, Transgenic RNA, Small Interfering/genetics,pharmacology T-Lymphocytes, Regulatory/immunology,metabolism,pathology Tumor Escape/genetics,immunology
Chemicals
Antigens, Neoplasm HMGB1 Protein IL10 protein, human RNA, Small Interfering Interleukin-10
Authors & Affiliations
3 authors, click to expand affiliations / ORCID
Liu Zuqiang
Department of Dermatology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA.
Falo Louis D
You Zhaoyang
References (44)
44 references, click to expand
  1. Danger signaling protein HMGB1 induces a distinct form of cell death accompanied by formation of giant mitochondria.
    Cancer Res. 2010 Nov 1;70(21):8558-68 PMID: 20959471
  2. Interleukin-10: new perspectives on an old cytokine.
    Immunol Rev. 2008 Dec;226:205-18 PMID: 19161426
  3. Induction of immunological tolerance by apoptotic cells requires caspase-dependent oxidation of high-mobility group box-1 protein.
    Immunity. 2008 Jul 18;29(1):21-32 PMID: 18631454
  4. Tumor regulatory T cells potently abrogate antitumor immunity.
    J Immunol. 2009 May 15;182(10):6160-7 PMID: 19414769
  5. Tumor cells convert immature myeloid dendritic cells into TGF-beta-secreting cells inducing CD4+CD25+ regulatory T cell proliferation.
    J Exp Med. 2005 Oct 3;202(7):919-29 PMID: 16186184
  6. Fueling inflammation at tumor microenvironment: the role of multiligand/RAGE axis.
    Carcinogenesis. 2010 Mar;31(3):334-41 PMID: 20028726
  7. Regulatory T cells and treatment of cancer.
    Curr Opin Immunol. 2008 Apr;20(2):241-6 PMID: 18508251
  8. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival.
    Nat Med. 2004 Sep;10(9):942-9 PMID: 15322536
  9. T cell-derived IL-10 promotes lung cancer growth by suppressing both T cell and APC function.
    J Immunol. 1999 Nov 1;163(9):5020-8 PMID: 10528207
  10. HMGB1 is an endogenous immune adjuvant released by necrotic cells.
    EMBO Rep. 2004 Aug;5(8):825-30 PMID: 15272298
  11. HMGB1: a two-headed signal regulating tumor progression and immunity.
    Curr Opin Immunol. 2008 Oct;20(5):518-23 PMID: 18599281
  12. A unique subset of CD4+CD25highFoxp3+ T cells secreting interleukin-10 and transforming growth factor-beta1 mediates suppression in the tumor microenvironment.
    Clin Cancer Res. 2007 Aug 1;13(15 Pt 1):4345-54 PMID: 17671115
  13. Endogenous damage-associated molecular pattern molecules at the crossroads of inflammation and cancer.
    Neoplasia. 2009 Jul;11(7):615-28 PMID: 19568407
  14. Interleukin-10-secreting type 1 regulatory T cells in rodents and humans.
    Immunol Rev. 2006 Aug;212:28-50 PMID: 16903904
  15. Altered immune responses in interleukin 10 transgenic mice.
    J Exp Med. 1997 Jun 16;185(12):2101-10 PMID: 9182682
  16. HMGB1 mediates endogenous TLR2 activation and brain tumor regression.
    PLoS Med. 2009 Jan 13;6(1):e10 PMID: 19143470
  17. Potent tumor-specific protection ignited by adoptively transferred CD4+ T cells.
    J Immunol. 2008 Sep 15;181(6):4363-70 PMID: 18768895
  18. The regulation of IL-10 production by immune cells.
    Nat Rev Immunol. 2010 Mar;10(3):170-81 PMID: 20154735
  19. Interleukin-10 and the immune response against cancer: a counterpoint.
    J Leukoc Biol. 2005 Nov;78(5):1043-51 PMID: 16204623
  20. Hallmarks of cancer: the next generation.
    Cell. 2011 Mar 4;144(5):646-74 PMID: 21376230
  21. Short hairpin RNA (shRNA) constructs targeting high mobility group box-1 (HMGB1) expression leads to inhibition of prostate cancer cell survival and apoptosis.
    Int J Oncol. 2009 Feb;34(2):425-31 PMID: 19148477
  22. Blockade of RAGE-amphoterin signalling suppresses tumour growth and metastases.
    Nature. 2000 May 18;405(6784):354-60 PMID: 10830965
  23. High-mobility group box 1 and cancer.
    Biochim Biophys Acta. 2010 Jan-Feb;1799(1-2):131-40 PMID: 20123075
  24. Myeloid-derived suppressor cells as regulators of the immune system.
    Nat Rev Immunol. 2009 Mar;9(3):162-74 PMID: 19197294
  25. Enhanced immunity by NeuEDhsp70 DNA vaccine Is needed to combat an aggressive spontaneous metastatic breast cancer.
    Mol Ther. 2005 Jun;11(6):941-9 PMID: 15922965
  26. Tumor evasion of the immune system by converting CD4+CD25- T cells into CD4+CD25+ T regulatory cells: role of tumor-derived TGF-beta.
    J Immunol. 2007 Mar 1;178(5):2883-92 PMID: 17312132
  27. The Foxp3+ regulatory T cell: a jack of all trades, master of regulation.
    Nat Immunol. 2008 Mar;9(3):239-44 PMID: 18285775
  28. DNA alkylating therapy induces tumor regression through an HMGB1-mediated activation of innate immunity.
    J Immunol. 2011 Mar 15;186(6):3517-26 PMID: 21300822
  29. Plasmacytoid dendritic cells from mouse tumor-draining lymph nodes directly activate mature Tregs via indoleamine 2,3-dioxygenase.
    J Clin Invest. 2007 Sep;117(9):2570-82 PMID: 17710230
  30. Masquerader: high mobility group box-1 and cancer.
    Clin Cancer Res. 2007 May 15;13(10):2836-48 PMID: 17504981
  31. Strategies for use of IL-10 or its antagonists in human disease.
    Immunol Rev. 2008 Jun;223:114-31 PMID: 18613832
  32. The effect of high-mobility group box 1 protein on activity of regulatory T cells after thermal injury in rats.
    Shock. 2009 Mar;31(3):322-9 PMID: 18665051
  33. The cytokine activity of HMGB1.
    J Leukoc Biol. 2005 Jul;78(1):1-8 PMID: 15734795
  34. Tumor-evoked regulatory B cells promote breast cancer metastasis by converting resting CD4⁺ T cells to T-regulatory cells.
    Cancer Res. 2011 May 15;71(10):3505-15 PMID: 21444674
  35. Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy.
    Nat Med. 2007 Sep;13(9):1050-9 PMID: 17704786
  36. Mechanisms of foxp3+ T regulatory cell-mediated suppression.
    Immunity. 2009 May;30(5):636-45 PMID: 19464986
  37. Endogenous HMGB1 regulates autophagy.
    J Cell Biol. 2010 Sep 6;190(5):881-92 PMID: 20819940
  38. Reversion of immune tolerance in advanced malignancy: modulation of myeloid-derived suppressor cell development by blockade of stem-cell factor function.
    Blood. 2008 Jan 1;111(1):219-28 PMID: 17885078
  39. Regulatory T cells, tumour immunity and immunotherapy.
    Nat Rev Immunol. 2006 Apr;6(4):295-307 PMID: 16557261
  40. HMGB1 and RAGE in inflammation and cancer.
    Annu Rev Immunol. 2010;28:367-88 PMID: 20192808
  41. Suppression of dendritic cells by HMGB1 is associated with lymph node metastasis of human colon cancer.
    Pathobiology. 2009;76(4):155-62 PMID: 19571604
  42. Tumor-derived CD4(+)CD25(+) regulatory T cell suppression of dendritic cell function involves TGF-beta and IL-10.
    Cancer Immunol Immunother. 2007 Jan;56(1):48-59 PMID: 16612596
  43. HMGB1: guiding immunity from within.
    Trends Immunol. 2005 Jul;26(7):381-7 PMID: 15978523
  44. High-mobility group box 1 (HMGB1) protein at the crossroads between innate and adaptive immunity.
    Immunol Rev. 2007 Dec;220:35-46 PMID: 17979838
Article Info
Journal
Journal of immunology (Baltimore, Md. : 1950)
Abbr.
J Immunol
ISSN
1550-6606
Published
2011-07-01
Epub
2011-00-03
Pages
118-25
Language
English
Region
United States
NLM ID
2985117R
PMCID
PMC3119781
Subset
IM
Grants
NCI NIH HHS · R01 CA106662 · United States
NCI NIH HHS · R01 CA108813 · United States
NCI NIH HHS · R01 CA108813-04 · United States
NIAID NIH HHS · R01 AI076060 · United States
NCI NIH HHS · R01 CA108813-05 · United States
NCI NIH HHS · R01 CA108813-02 · United States
NCI NIH HHS · P01CA73743 · United States
NCI NIH HHS · R01 CA108813-03 · United States
NCI NIH HHS · R01CA108813 · United States
NCI NIH HHS · P01 CA073743 · United States
NCI NIH HHS · R01 CA108813-04S2 · United States
NCI NIH HHS · CA106662 · United States
NIAID NIH HHS · R01AI076060 · United States
NCI NIH HHS · R01CA108813-04S2 · United States
NCI NIH HHS · R01 CA108813-01A1 · United States
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com